## Invitation to Local Pharmaceutical Manufacturers to submit Expression of Interest (EOI) for the Manufacture of Chlorhexidine

To support national and global efforts to increase access to and the affordability of products for newborn umbilical cord care, the National Agency for Food and Drug Administration and Control (NAFDAC), together with United States Agency for International Development (USAID), the United States Pharmacopoeia (USP). Promoting the Quality of Medicines (PQM) program, and Program for Appropriate Technology in Health (PATH) invite pharmaceutical manufacturers to submit Expressions of Interest (EOIs) for inspection of their manufacturing sites to assess compliance with good manufacturing practices (GMP) for production of 7.1% chlorhexidine digluconate gel for umbilical cord care.

If the assessment demonstrates that a product and its corresponding manufacturing site meet quality assurance standards as per accepted international standards, the product as well as the manufacturer will be included in the list of products that are considered to be acceptable for procurement by Nigeria Ministry of Health and other procurement agencies. For further details, the full notice inviting expressions of interests may be requested from the email address given below.

Interested parties should submit the following information to eoi@insighthc.org by May 17<sup>th</sup> 2013.

- 1. Cover letter expressing interest in receiving technical assistance for the manufacture of the selected pharmaceutical product.
- 2. A list of chlorhexidine products currently being produced or plan on producing.